Barbara Balogh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Barbara Balogh has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Ildikó Bácskay
Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Debrecen, 4002 Debrecen, Hungary
3 shared publications - Zoltán Ujhelyi
Department of Industrial Pharmaceutical Technology, Faculty of Pharmacy, University of Debrecen, Rex Ferenc Street 1, H-4002 Debrecen, Hungary
3 shared publications - Ágota Pető
Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Debrecen, Rex Ferenc Street 1, H-4002 Debrecen, Hungary
3 shared publications - Pálma Fehér
Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Debrecen, Rex Ferenc Utca 1, H-4002 Debrecen, Hungary
2 shared publications - Dávid Sinka
Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Debrecen, 4032 Debrecen, Hungary
1 shared publication - Dóra Kósa
Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Debrecen, Nagyerdei Körút 98, 4032 Debrecen, Hungary
1 shared publication
Latest Publications
- Open Access
- 19 March 2026
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 221, 107510
In Vitro Investigation of Tapinarof-Loaded Nanogels in an Imiquimod-induced HaCaT–THP-1 Co-Culture Model
- 19 March 2026
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 221, 107510
Open AccessIn Vitro Investigation of Tapinarof-Loaded Nanogels in an Imiquimod-induced HaCaT–THP-1 Co-Culture Model
- Open Access
- 1 June 2025
- Published by MDPI AG in Pharmaceutics
- Vol. 17 (6) , 731
Tapinarof Nanogels as a Promising Therapeutic Approach
Psoriasis is a chronic inflammatory skin disease characterised by increased oxidative stress, the overproliferation of keratinocytes, the accumulation of inflammatory mediators, and skin barrier damage. Although a number of therapeutic options are available, finding long-term treatments that are well-tolerated and patient-friendly treatments remains a challenge. Tapinarof is a new type of aryl hydrocarbon receptor (AhR) modulator that has recently attracted attention as a promising non-steroidal alternative. However, its application may be limited by its poor water solubility and low degree of skin penetration. Nanotechnology-based drug carriers, specially nanogels, offer new opportunities to overcome these limitations by combining the advantages of targeted drug delivery and enhanced skin penetration. Furthermore, nanogel formulations can improve skin hydration and support the restoration of skin barrier function, which are important in the treatment of psoriasis. This review focuses on current and emerging therapeutic approaches, with particular emphasis on the potential of incorporating tapinarof into nanogel formulations as a novel alternative to topical psoriasis treatment.
- 1 June 2025
- Published by MDPI AG in Pharmaceutics
- Vol. 17 (6) , 731
Open AccessTapinarof Nanogels as a Promising Therapeutic Approach
Psoriasis is a chronic inflammatory skin disease characterised by increased oxidative stress, the overproliferation of keratinocytes, the accumulation of inflammatory mediators, and skin barrier damage. Although a number of therapeutic options are available, finding long-term treatments that are well-tolerated and patient-friendly treatments remains a challenge. Tapinarof is a new type of aryl hydrocarbon receptor (AhR) modulator that has recently attracted attention as a promising non-steroidal alternative. However, its application may be limited by its poor water solubility and low degree of skin penetration. Nanotechnology-based drug carriers, specially nanogels, offer new opportunities to overcome these limitations by combining the advantages of targeted drug delivery and enhanced skin penetration. Furthermore, nanogel formulations can improve skin hydration and support the restoration of skin barrier function, which are important in the treatment of psoriasis. This review focuses on current and emerging therapeutic approaches, with particular emphasis on the potential of incorporating tapinarof into nanogel formulations as a novel alternative to topical psoriasis treatment.
- Open Access
Formulation and Evaluation of Different Nanogels of Tapinarof for Treatment of Psoriasis
Psoriasis is an immune-mediated skin condition. There are many therapeutic options for its treatment; however, none of them is completely effective. Tapinarof is a promising new active substance; it was recently approved by the FDA for the treatment of psoriasis. The aim of our study was to prepare topical nanoformulations of the active substance to improve its bioavailability and therapeutic effect. The biocompatibility investigation of the formulations was carried out by MTT assay, and the size distribution of the preparations was investigated by DLS. In parallel, the rheological properties and the texture were examined, and the in vitro release of tapinarof was assessed by the Franz diffusion method. An in vitro wound healing assay was also carried out to study the drug’s properties. Our results show that the preparations were safe on HaCaT cells. The particle size of the formulations was proven to be in the nanoscale range. In the in vitro release studies, nanogel II. showed greater release of the active substance. According to the wound healing assay, incorporation of the drug into nanoformulations increases the antiproliferative and antimigration activity of the drug. Overall, nanoformulations of tapinarof were successfully prepared, and our results suggest that they can be a useful addition to the current therapeutic practice of psoriasis.
Open AccessFormulation and Evaluation of Different Nanogels of Tapinarof for Treatment of Psoriasis
Psoriasis is an immune-mediated skin condition. There are many therapeutic options for its treatment; however, none of them is completely effective. Tapinarof is a promising new active substance; it was recently approved by the FDA for the treatment of psoriasis. The aim of our study was to prepare topical nanoformulations of the active substance to improve its bioavailability and therapeutic effect. The biocompatibility investigation of the formulations was carried out by MTT assay, and the size distribution of the preparations was investigated by DLS. In parallel, the rheological properties and the texture were examined, and the in vitro release of tapinarof was assessed by the Franz diffusion method. An in vitro wound healing assay was also carried out to study the drug’s properties. Our results show that the preparations were safe on HaCaT cells. The particle size of the formulations was proven to be in the nanoscale range. In the in vitro release studies, nanogel II. showed greater release of the active substance. According to the wound healing assay, incorporation of the drug into nanoformulations increases the antiproliferative and antimigration activity of the drug. Overall, nanoformulations of tapinarof were successfully prepared, and our results suggest that they can be a useful addition to the current therapeutic practice of psoriasis.